Somatropin therapy in italian adults with growth hormone deficiency

Abstract

Background

In adult population, Growth Hormone Deficiency (GHD) is a complex clinical condition with heterogeneity of causes and duration. Growth Hormone (GH) replacement therapy has beneficial effects entailing a chronic and expensive use. Therefore, entity, appropriateness and standardization of GHD treatment need to be accurately analysed.

In Italy, the epidemiological surveillance on somatropin therapy is entrusted to the National Register of Growth Hormone Therapy (Registro Nazionale degli Assuntori dell’Ormone della Crescita-RNAOC) by the Italian Regulation, in accordance of which the RNAOC-database is collecting the notifications of somatropin prescriptions.

Methods

Aim of this study is to analyse data on somatropin-treated adult population communicated to the RNAOC by the specialist centres of 15 Italian regions and 2 autonomous provinces.

Results

From 2011 to 2019, the somatropin-treated adults were 970 with 4061 examinations (1.21 ± 0.33 visits/year).

The diagnoses were: hypopituitarism (n = 579); hypophysectomy (n = 383); and congenital GHD (n = 3). Five subjects were addressed with diagnoses not included in the regulation.

The starting posology of somatropin was 0.320 (± 0.212) mg/day, 0.292 (± 0.167) mg/day in male and 0.360 (± 0.258) in female patients, with 7 administrations/week in 70.31% of the prescriptions. The differences in posology by gender persisted at 10th year of the follow-up. Starting dosage was higher in patients diagnosed with adult GHD before the age of 30 (0.420 ± 0.225 mg/day), with a progressive decrease of the dosage during the follow-up.

Conclusions

This is the first report on adult GH treatment, describing numbers, diagnoses, and pharmaceutical prescriptions associated to somatropin therapy in a large cohort of Italian GHD-adults.

Background

In adult population, Growth Hormone Deficiency (GHD) is a syndrome affecting metabolic pathways, adipose and bone tissues, cardiovascular system, etc. Patients could experience increased central adiposity, hyperlipidaemia, and augmented predisposition to atherogenesis, with important impact on the quality of life, including an increased risk of mortality, predominantly due to cardiovascular diseases [1, 4].

It has been demonstrated that GH replacement therapy has beneficial effects on adult GHD. However, it should be considered that this treatment implies a long-term use, with considerable costs and safety concerns. In addition, GHD diagnostic problems have still to be clearly identified.

In this context, reliable epidemiological data on adult GHD are fundamental to measure size, turnover and duration of treatment but they are difficult to obtain due to the heterogeneity of causes and the complexity in diagnosis. In adulthood, GHD could result from the persistency of a child-onset GHD (CO-GHD) or, in the majority of cases, an adult-onset (AO-GHD) condition, with the corresponding difference in pathogenesis, idiopathic or acquired. Another important variable is represented by the diagnostic tests in their application, standardization, and cut-off limits. One more issue is that most of the studies on somatropin treatment are sponsored trials, targeting specific diagnoses or patients.

Given the limited amount of information on growth hormone therapy when applied in the general population, the Italian Ministry of Health at the end of the ‘80s implemented the National Register of Growth Hormone Therapy (Registro Nazionale degli Assuntori dell’Ormone della Crescita-RNAOC). In 2000, the Italian Medicines Agency (AIFA) defined the diagnoses for which somatropin could be reimbursed by the National Health Service (Note#39), with specific criteria for each age category [5–9], and commissioned to the Italian National Institute of Health (Istituto Superiore di Sanità) the collection and analysis of data [10].

Aim of this study is to describe characteristics and therapy in recombinant GH (rGH)-treated adults in the field practice in Italy. The study was conducted on the adult subjects treated with somatropin in 156 centres of 15 Italian regions and 2 autonomous provinces from January 1st 2011 to December 31st 2019.

Methods

The Italian National Health Service provides adults diagnosed with hypopituitarism, hypophysectomy and congenital GH deficiency, with free-of-charge somatropin. They are diagnosed and treated by the specialists of the clinical centres identified by Italian regions and autonomous provinces [7, 8].

For each treated patient a standard form is to be filled in at each visit and forwarded to the RNAOC at the Italian National Institute of Health.

Since 2011, RNAOC is based on online reporting of rGH prescription forms including a minimum set of mandatory data, i.e. patient personal details, diagnosis and therapy. More details on the web-based RNAOC have already been reported [10].

Patients and data collection

From January 1st 2011 to December 31st 2019, all information relating to patients aging > 18 with a diagnosis in the group of “adult age” at first visit was selected from the RNAOC database. The following data were considered for each patient: patient’s personal data (date of birth, gender, residence), diagnosis, visits with date of visit, and prescriptions (product, daily posology and weekly frequency of administration).

Patients were followed up until the first of the following events: discontinuation of therapy for any reason, admission to hospital, death. Patients who moved from one clinical centre to another one were considered as treatment continues.

Data underwent quality checks at the data-entry and saving phases, and on the database.

Patients with diagnoses related to the paediatric or the transition age, or not coherent with the chronological age at first visit, were excluded. When subsequent diagnoses were reported, only the first one was considered.

Posology of somatropin therapy was adopted in mg/day. When the weekly frequency of administration was different from 7 days/week, the posology was normalized at mg/day recomputing the total weekly quantity to 7 days.

To calculate the posology according to the year of follow-up for each patient, the follow-up visit closer to the year category was considered.

Ethic statement

The data collection procedures from clinical units to the RNAOC are in agreement with the Italian legislation for the personal data protection (Legislative Decree 196/2003) and have been updated according to the current European regulation (General Data Protection Regulation, GDPR 2016/679).

Informed consent is not required because processing personal data is essential in order to carry out surveillance activities and drug reimbursement. Anyway, to ensure compliance with the GDPR, an information notice for patients is available in the RNAOC-web platform, with the description of personal data treatment in terms of objective, methods, and ownership.

Statistical analysis

Statistical analysis was carried out using the STATA software system (StataCorp LLC, TX, USA).

Descriptive statistics, Student’s t-test and ANOVA tests were used to analyse the data. A level of P < 0.05 was considered significant.

Results

At the end of 2019, 15 Italian regions and 2 autonomous provinces had joined RNAOC with 156 clinical centres, and 208 medical outpatients’ facilities indicated as official “prescribing centres”. The accredited clinicians were 350.

During the study period (January 1st 2011 - December 31st 2019), 7332 somatropin treated subjects were reported to RNAOC with some heterogeneity among the regions of the clinical specialist centres.

The subjects older than 18 years with a diagnosis of GHD in the group of “adult age” were 970, 566 (58.35%) males (M) and 404 (41.65%) females (F), representing the 13.23% of all the cases reported to the RNAOC. A total of 4061 visits were carried out and submitted. Discontinuation of treatment was reported in 74 subjects, nine of which were due to death. The frequency of follow-up visits was 1.21 ± 0.33 per year.

In the period 2011–2019, 90.75 ± 75.82 (mean ± SD) adult patients were registered each year and the age at first visit was 48.68 ± 15.60 years (range 18.17–86.89).

Diagnoses in somatropin-treated adults, total and by gender, are reported in Table 1.

Table 1.

Diagnoses of Growth Hormone Deficiency in adulthood according to AIFA Note#39, as reported to the RNAOC-web platform by the clinical specialist centres from January 1st 2011 to December 31st 2019

Adulthood diagnoses	Subjects		Males		Females
	n.	%	n.	%	n.	%
Hypopituitarism: idiopathic, autoimmune hypophysitis, post-cranio-encephalic trauma, surgery or irradiation for sellar or parasellar tumors, empty sella, Sheehan syndrome	579	59.69	338	59.72	241	59.65
Hypopituitarism: post total or partial hypophysectomy	383	39.48	223	39.40	160	39.60
Congenital GH deficiency with demonstrated genetic defect	3	0.31	1	0.18	2	0.50
Not included in Note#39	5	0.52	4	0.70	1	0.25
Total	970		566		404

These results show that replacement therapy notifications in adult GHD were slightly prevalent in males with no statistically significance between genders. The group of hypopituitarisms not due to surgical ablation was the most frequent cause of adult GHD.

There were 377 subjects with additional pituitary deficiencies: FSH/LH and TSH deficiencies were the most frequent, in 302 (80.11%) and 299 (79.31%) subjects respectively. The pituitary hormone deficiencies were often associated (Table 2).

Table 2.

Number and percentage of somatropin-treated adults with diagnosis of additional pituitary hormone deficiencies registered to the RNAOC-web platform by the specialists of the clinical centres from January 1st 2011 to December 31st 2019

Pituitary hormone deficiency (n.)	Subjects n. (%)
1	89 (23.61)
2	75 (19.89)
3	149 (39.52)
4	64 (16.98)
Total	377 (100.00)

For the starting dosage, the mean daily posology at first visit (n = 970) was 0.320 (± 0.212) mg/day, lower in M, 0.292 (± 0.167) mg/day, than in F, 0.360 (± 0.258), (p < 0.001), with a frequency of 7 administrations/week in 70.31% of subjects (69.61% in M and 71.29% in F. A percentage of 16.60% of patients received 6 administrations/week.

The initial posology was analysed as related to the diagnosis, showing differences among the causes of GHD and the highest initial dosage in congenital GH deficiency (Table 3).

Table 3.

Somatropin daily posology (mg/day) prescribed in GHD-adults according to the diagnosis, as reported to the RNAOC-web platform by the clinical specialist centres from January 1st 2011 to December 31st 2019

Adulthood diagnoses	Starting daily posology (mg/day)		5-years daily posology (mg/day)
	Mean	SD (±)	Mean	SD (±)
Hypopituitarism: idiopathic, autoimmune hypophysitis, post-cranio-encephalic trauma, surgery or irradiation for sellar or parasellar tumors, empty sella, Sheehan syndrome	0.337	0.227	0.348	0.266
Hypopituitarism post total or partial hypophysectomy	0.296	0.188	0.304	0.192
Congenital GH deficiency with demonstrated genetic defect	0.424	0.128	-	-
Not included in Note#39	0.206	0.082	0.229	0.049
All diagnoses	0.320	0.212	0.329	0.238

At 5-year follow-up visit, the daily posology by group of diagnoses does not substantially change. A little, not significant, increment was observed possibly as an effect of the difference in gender compliance.

To analyse the daily posology during the long-term follow-up, all the available visits for each subject were considered.

On 5th year follow-up visits (n = 267) the mean posology was 0.329 (± 0.238) mg/day, 0.274 (± 0.138) mg/day in M (n = 151) and 0.400 (± 0.311) mg/day in F (n = 116) (p < 0.001).

At 10th year follow-up visits (n = 40) the mean daily posology was 0.334 (± 0.252) mg/day, 0.266 (± 0.144) mg/day in M (n = 27) and 0.474 (± 0.361) mg/day in F (n = 13) (p = 0.0125) (Fig. 1).

Fig. 1.

Somatropin daily posology (mg/day) at the follow-up visits of GHD-adults registered in the RNAOC-database by the specialists of the clinical centres from January 1st 2011 to December 31st 2019, gender-disaggregate (- - - Males; ---- Females)

The diversity in posology by gender was maintained during the follow-up visits with a statistically significant difference all over the follow-up years (Fig. 1; Table 4).

Table 4.

Counting of somatropin prescriptions at the 10-years follow-up visits gender-disaggregate

Gender	Follow-up visits (year)
	1	2	3	4	5	6	7	8	9	10
Male	566	318	253	173	133	82	35	23	19	21
Female	405	210	180	136	93	56	28	14	16	12

The daily dosage was also analysed considering the age of subjects at the first administration since guidelines suggest a lower quantity in older patients and a major need in younger patients, especially when they are child-onset GHD. Thus, subjects were divided into 3 age groups: <=30, 31–60 and > 60 years old at first visit.

According to the recommendations, the starting administered daily posology was lower in the older group (0.246 ± 0.117 mg/day) and higher in the younger one (0.420 ± 0.225 mg/day), with a statistically significant difference among age groups for all the years of the follow-up visits (p < 0.001) (Fig. 2; Table 5).

Fig. 2.

Somatropin daily posology (mg/day) prescribed in GHD-adults registered in the RNAOC database by the clinical specialist centres from January 1st 2011 to December 31st 2019, split according to age groups (---- ≤30; - - - -31-60; …. >60 years old)

Table 5.

Counting of somatropin prescriptions at the 10-years follow-up visits split according to age groups

Age (years)	Follow-up visits (year)
	0	1	2	3	4	5	6	7	8	9	10
≤ 30	150	150	92	70	50	41	27	18	14	13	10
31–60	574	574	366	298	230	167	100	49	40	34	27
> 60	246	246	134	113	79	59	37	10	5	4	3

The difference between males and females was statistically significant among age groups at 2 years of follow-up. These differences were kept until 5th year in the youngest group, and in the oldest one for 2 years of follow-up. In the intermediate group of age, males and females followed up for 10 years continued to receive statistically different doses.

In detail, in the younger group, the difference between genders was confirmed (F: 0.444 ± 0.237 mg/day vs. M: 0.402 ± 0.216 mg/day), and a progressive decrease of somatropin administration during 10 years of follow-up was observed.

The biosimilar somatropin was prescribed for 84 “naïve” patients at the first visit (9.26%) and 40 patients were “shifted” to the biosimilar product at the follow-up visits (4.12%).

Discussion

This is the first report from the Italian National Register of Growth Hormone Therapy (RNAOC) on somatropin treatment in adults during the period 2011–2019. Data are communicated by the clinical specialist centres of 15 Italian regions and 2 autonomous provinces, covering approximately 55% of the Italian population (over 32 million people).

Throughout 10 years of data collection, 970 adults treated with somatropin were registered, representing the 13.23% of the rGH prescriptions notified to RNAOC that also collects paediatric and transition age treatments.

The number of subjects reported to the register is not homogeneous among regions probably due to the incomplete adherence of the specialist centres to the mandatory notification of prescriptions, or to local regulations. Similar geographical heterogeneity was observed in the prevalence of somatropin use in a wide cohort of patients from six Italian regions, also evidencing that no rGH consumption pattern could be identified across the Country [11].

Mean baseline age was 48.68 ± 15.60 years, quite similar to that registered in other large surveillance databases containing GHD patients [12–15]. Furthermore, the sex distribution of patients showed that there is no difference between genders, confirming studies from the Dutch National Register study [16] and other European studies based on the epidemiology of hypopituitarism [17, 18]. On the contrary, data obtained from a study combining 3 Danish national registries showed a higher incidence rate in males compared to females in the CO-GHD group and in the AO-GHD group over 45 years of age [19].

These discordances could arise from the heterogeneity of data collections that are based on different criteria, e.g., collection period, specific diagnoses, age of onset, replacement therapy and medicine distribution patterns. In detail, Danish data are the merging of three registries, patients with a cancer diagnosis, the national patient registry, and the cause of death registry from 1980 to 1999, to identify subjects with a diagnosis of GHD using hospitals or city archives [19]. The Dutch register collects patients with severe GHD registered in The Netherlands in the period mid 1998–2008 [16]. Our data are collected on the basis of the Italian regulation established by the authority on medicines that is targeted on pharmacosurveillance rather than on GHD patients and, consequently, the RNAOC database gathers information as required by law with the specific objectives of appropriateness and monitoring of drug consumption [10].

For these reasons, there is a concrete difficulty in comparing data and in estimating the real numbers of adult GHD as well.

According to the AIFA Note#39, adult GHD diagnoses notified to RNAOC are grouped in: hypopituitarism, hypophysectomy, and congenital GH deficiency. The analysis of RNAOC-notified diagnoses shows the prevalence of GHD resulting from hypopituitarism, with no gender differences.

Our data are in line with the evidence that the aetiology of GHD in adults corresponds to the causes of hypopituitarism. In literature, about two-thirds of cases are caused by pituitary tumours or other parasellar masses or resulted from surgery or radiation, and less common causes are traumatic brain injury, granulomatosis, infectious or brain haemorrhages [17, 22, 23]. A small percentage of adult GHD is due to a persistence of GHD in childhood, representing 15–35% of cases in different reports [24, 25]. Moreover, GH is typically the first hormone to become clearly deficient in the majority of the different causes of hypopituitarism [24].

To support these data, about 1/3 of the RNAOC adult somatropin-treated subjects display associated pituitary hormone deficiencies and 56.5% of them has three or more pituitary hormone deficiencies.

GH therapy in adult GHD has been shown to be crucial in supporting morphological, metabolic, physical, and psychological problems. However, there are still some controversies regarding safety, costs, way of administration, and evaluation of benefits. Considering these issues, the replacement regimen has been object of deep evaluation and dosing plans are proposed in guidelines from scientific associations. Individualized treatment is recommended starting with low dose considering the gender, a posology of 0.2 mg/day for men and 0.3 mg/day for women, and the age, in subjects < = 30 years old: 0.4–0.5 mg/day; in adults aged between 31 and 60 years: 0.2–0.3 mg/day; and in subjects > 60 years old: 0.1–0.2 mg/day. Exception is represented by CO-GHD patients who, in general, initially need 50% of the paediatric dosage. Then, a gradual increase of 0.1–0.2 mg/day, if necessary, and an annual assessment should be performed [26–30].

Prescriptions reported in the RNAOC database highlight that the mean initial daily posology of somatropin was slightly higher than suggested by the international recommendations and guidelines, but it becomes aligned when the age groups of patients are considered, demonstrating that the starting doses were adjusted for the age of subjects. Interestingly, the younger rGH treated subjects gradually decreased the daily dosage during the years and reached the posology of the other age groups.

The recommendations to take into account gender are complied with and the differences in dosage are also maintained during the follow-up visits.

Furthermore, the recommendation about the frequency of medical examinations is followed.

One relevant concern for somatropin therapy is about costs that could be reduced by implementing the available somatropin biosimilar. In Italy, the national report on medicine consumption describes a mean of 9.45% of biosimilar somatropin prescriptions with respect to the total rGH preparations in the years 2011–2019, with a progressive increase from 5.5 to 18.2% [31].

In the same years, the prescriptions notified to RNAOC web showed that the adoption of biosimilar somatropin in adults is rather low (13.38%). These data confirm results from a recent extensive study on total rGH consumption in six Italian centres that evidenced a mean of 7.2% of biosimilar rGH users in years 2009–2014, a low percentage compared to other biosimilars (e.g., epoetin alpha and filgrastim), with a variable proportion across different geographical areas. The authors speculate that this variability could be due to the different health-care policies adopted at a loco-regional level, differences in patients’ access to different rGH, different tender procedures for originators and biosimilars purchase by public structures, and the still ongoing scepticism about biosimilars, especially when target patients are paediatric as for rGH [11].

Interestingly, the data on total somatropin biosimilar use are comparable to the results in adult rGH-treated patients registered in RNAOC database.

Definitively, our analysis describes the management of a large Italian cohort of GHD adults treated with somatropin by clinical specialist centres following the regulation by the competent authorities based on updated guidelines indicated by the experts.

The relevance of this report lies in the fact that our data originate from a register appointed for surveillance by national public institutions, and that it can provide complementary information to placebo-controlled, randomized clinical or sponsored trials, by making available epidemiological data, large patient cohorts and pharmaceutical prescriptions. Therefore, the RNAOC database is a useful tool in collecting data from field practice, despite its limits including partial information about treatment efficacy or side effects.

Conclusions

In conclusion, RNAOC supplies information to the National Health Service, the regional health authorities and the scientific community on numbers, diagnoses, appropriateness, working activity of clinical specialist centres and pharmaceutical consumption related to somatropin therapy in adults.

Abbreviations

AIFA

Agenzia Italiana del Farmaco-Italian Medicines Agency

AO-GHD

dult-onset Growth Hormone Deficiency

CO-GHD

child-onset Growth Hormone Deficiency

GDPR

General Data Protection Regulation

GH

Growth Hormone

GHD

Growth Hormone Deficiency

rGH

recombinant Growth Hormone

RNAOC

Registro Nazionale degli Assuntori dell’Ormone della Crescita-National Register of Growth Hormone Therapy

Authors' contributions

FP, DR, MV, and EA carried out the study, and participated in collecting data. FP drafted the manuscript. DR performed the statistical analysis. AV helped to draft the manuscript. PR managed the IT platform. All authors read and approved the final manuscript.

Funding

This work was supported by the National Institute of Health (Istituto Superiore di Sanità) and the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA) to establish and supervise the application of the AIFA Notes. The funding bodies had no rule in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials

RNAOC database is stored at the IT Service of National Institute of Health (Istituto Superiore di Sanità).

Data Availability: Restrictions apply to the availability of data generated or analyzed during this study to preserve patient confidentiality or because they were used under license. The corresponding author will on request detail the restrictions and any conditions under which access to some data may be provided.

Declarations

Ethic approval and consent to participate

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

The data collection procedures from clinical units to the RNAOC are in agreement with the Italian legislation for the personal data protection (Legislative Decree 196/2003) and have been updated according to the current European regulation (General Data Protection Regulation, GDPR 2016/679).

This observational study is included in the Register of Data Treatments of the National Institute of Health (Istituto Superiore di Sanità).

Informed consent is not required because processing personal data is essential in order to carry out surveillance activities and drug reimbursement. Anyway, to ensure compliance with the GDPR, an information notice for patients is available in the RNAOC-web platform, with the description of personal data treatment in terms of objective, methods, and ownership. For the retrospective study, formal consent is not required.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no conflict of interest.